Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>BOCOMI: Many CN Innovative Drugs to Announce Blockbuster Data at ASCO Meeting w/ Record High No. of Selected CN Innovative Drug
Recommend 46 Positive 68 Negative 30 |
||||
|
||||
|
The H shares of pharma inclined today (29th). SINO BIOPHARM (01177.HK) advanced 5.5% to $4.42, while CSPC PHARMA (01093.HK) surged 11.6% after announcing its 1Q results. AKESO (09926.HK) leaped 4%, while WUXI APPTEC (02359.HK) swelled 6.6%. WUXI BIO (02269.HK) shot up 9.8%. The 2025 annual meeting of American Society of Clinical Oncology (ASCO) will be held from 30 May to 3 June in Chicago, the US, BOCOMI released a research report saying. On 22 May, the full abstract of the ASCO annual meeting was released, in which a number of innovative drug companies, including HENGRUI PHARMA (01276.HK), INNOVENT BIO (01801.HK), REMEGEN (09995.HK), Chia Tai Tianqing and SKB BIO-B (06990.HK), presented excellent clinical data. The number of Chinese innovative drugs selected in the abstract of 2025 ASCO annual meeting reached another new high, confirming that Chinese innovative drug companies achieved a leapfrog breakthrough in research & development competitiveness, with gradually increasing international influence, BOCOMI added. Considering the significant investment cost-performance ratio (CP ratio) of the sector, low institutional positions and continuous implementation of favorable policies related to the support of innovative drugs throughout the chain, the broker suggested that short-term focus can be placed on ANTENGENE-B (06996.HK) and other innovative drug stocks with rich short-term catalysts, high earnings growth or break-even point and greater flexibility in valuation; prescription drug companies with high performance growth + valuation multiple expansion potential, such as SIMCERE PHARMA (02096.HK) and HANSOH PHARMA (03692.HK), etc.. AAStocks Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
